ERBB2 and breast cancer: Although these preliminary findings need to be confirmed in larger cohorts of patients, it is plausible that the simultaneous evaluation of both calcifications and enhancement on CEM is particularly advantageous for distinguishing certain histologic subtypes given that different patterns of calcifications are known to be predicable of HER2-positive and luminal A breast cancer [37–39].